Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/13643
Title: Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-Year results from a prospective, randomized, double-blind, placebo-controlled study
Authors: Ali T. Taher
John Porter
Vip Viprakasit
Antonis Kattamis
Suporn Chuncharunee
Pranee Sutcharitchan
Noppadol Siritanaratkul
Renzo Galanello
Zeynep Karakas
Tomasz Lawniczek
Jacqueline Ros
Yiyun Zhang
Dany Habr
Maria Domenica Cappellini
American University of Beirut
UCL
Mahidol University
University of Athens
Chulalongkorn University
Universita degli Studi di Cagliari
Istanbul Tip Fakultesi
Novartis International AG
Novartis Pharmaceuticals
Universita degli Studi di Milano
Keywords: Biochemistry, Genetics and Molecular Biology;Immunology and Microbiology;Medicine
Issue Date: 2-Aug-2012
Citation: Blood. Vol.120, No.5 (2012), 970-977
Abstract: Nontransfusion-dependent thalassemia (NTDT) patients may develop iron overload and its associated complications despite receiving only occasional or no transfusions. The present 1-year, randomized, double-blind, placebo-controlled THALASSA (Assessment of Exjade in Nontransfusion-Dependent Thalassemia) trial assessed the efficacy and safety of deferasirox in iron-overloaded NTDT patients. Atotal of 166 patients were randomized in a 2:1:2:1 ratio to starting doses of 5 or 10 mg/kg/d of deferasirox or placebo. The means ± SD of the actual deferasirox doses received over the duration of the study in the 5 and 10 mg/kg/d starting dose cohorts were 5.7 ± 1.4 and 11.5 ± 2.9 mg/kg/d, respectively. At 1 year, the liver iron concentration (LIC) decreased significantly compared with placebo (least-squares mean [LSM] ± SEM, -2.33 ± 0.7 mg Fe/g dry weight [dw] , P = .001, and -4.18 ± 0.69 mg Fe/g dw, P < .001) for the 5 and 10 mg/kg/d deferasirox groups, respectively (baseline values [means ± SD], 13.11 ± 7.29 and 14.56 ± 7.92 mg Fe/g dw, respectively). Similarly, serum ferritin decreased significantly compared with placebo by LSM -235 and -337 ng/mL for the deferasirox 5 and 10 mg/kg/d groups, respectively (P < .001). In the placebo patients, LIC and serum ferritin increased from baseline by 0.38 mg Fe/g dw and 115 ng/mL (LSM), respectively. The most common drug-related adverse events were nausea (n = 11; 6.6%), rash (n = 8; 4.8%), and diarrhea (n = 6; 3.6%). This is the first randomized study showing that iron chelation with deferasirox significantly reduces iron overload in NTDT patients with a frequency of overall adverse events similar to placebo. © 2012 by The American Society of Hematology.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84864530218&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/13643
ISSN: 15280020
00064971
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.